With Rapid Uptake of Noninvasive Prenatal Screening, Many Question its Impact on Abortion | GenomeWeb

NEW YORK (GenomeWeb) – When Indiana passed a law in March that prohibited abortions based on fetal genetic abnormalities, proponents of the bill cited the ubiquity of noninvasive prenatal tests as evidence that women would increasingly pursue abortion to avoid having children with genetic defects. Although the law was ultimately struck down in June by a federal judge, it led many to question whether the premise that just because it is now easier to test for Down syndrome, more couples will in fact choose to terminate pregnancies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Startup companies are taking on personalized medicine, CNET reports.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.